Toxoplasmosis in a patient receiving ixekizumab for psoriasis.
作者信息
Lobo Yolanka, Holland Teagan, Spelman Lynda
机构信息
Veracity Clinical Research, Queensland, Australia.
Queensland Institute of Dermatology, Queensland, Australia.
出版信息
JAAD Case Rep. 2020 Feb 19;6(3):204-206. doi: 10.1016/j.jdcr.2020.01.005. eCollection 2020 Mar.
Abstract
摘要
相似文献
1
Toxoplasmosis in a patient receiving ixekizumab for psoriasis.一名接受司库奇尤单抗治疗银屑病的患者发生弓形虫病。
JAAD Case Rep. 2020 Feb 19;6(3):204-206. doi: 10.1016/j.jdcr.2020.01.005. eCollection 2020 Mar.
2
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.依奇珠单抗及其他美国食品药品监督管理局批准的生物制剂治疗中重度斑块型银屑病的额外应答者成本。
J Med Econ. 2017 Dec;20(12):1224-1230. doi: 10.1080/13696998.2017.1362413. Epub 2017 Aug 22.
3
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.依奇珠单抗改善患者报告的生殖器银屑病症状，与安慰剂相比，在一项随机、双盲研究中改善症状对性行为的影响。
J Sex Med. 2018 Nov;15(11):1645-1652. doi: 10.1016/j.jsxm.2018.09.004.
4
Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.司库奇尤单抗用于治疗中度至重度斑块状银屑病和银屑病关节炎的成人患者。
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1423-1433. doi: 10.1080/17512433.2016.1242409. Epub 2016 Oct 11.
5
Ixekizumab for the treatment of psoriasis: an update on new data since first approval.依奇珠单抗治疗银屑病：首次批准以来新数据的更新。
Expert Rev Clin Immunol. 2019 Feb;15(2):111-121. doi: 10.1080/1744666X.2019.1559730. Epub 2018 Dec 27.
6
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.在银屑病的 7 项临床试验中，来自 ixekizumab 的短期和长期安全性结果：依那西普比较和综合数据。
J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026. Epub 2016 Nov 23.
7
Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials.依奇珠单抗治疗银屑病：III 期临床试验综述。
Dermatol Ther (Heidelb). 2016 Mar;6(1):25-37. doi: 10.1007/s13555-016-0102-0. Epub 2016 Feb 24.
8
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.司库奇尤单抗治疗中重度斑块状银屑病的临床应用价值
Psoriasis (Auckl). 2017 Nov 16;7:65-72. doi: 10.2147/PTT.S129792. eCollection 2017.
9
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
10
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.在接受或未接受过生物疗法的中度至重度银屑病患者中使用司库奇尤单抗的治疗结果：两项III期随机研究的综合分析
J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685. doi: 10.1111/jdv.13990. Epub 2016 Nov 2.
引用本文的文献
1
IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review.一名有银屑病及复发史患者的白细胞介素-23阻断治疗：病例报告与综述
SAGE Open Med Case Rep. 2025 Feb 18;13:2050313X251320196. doi: 10.1177/2050313X251320196. eCollection 2025.
2
The influence of paternal overweight on sperm chromatin integrity, fertilization rate and pregnancy outcome among males attending fertility clinic for IVF/ICSI treatment.父亲超重对接受 IVF/ICSI 治疗的男性精子染色质完整性、受精率和妊娠结局的影响。
BMC Pregnancy Childbirth. 2022 Aug 5;22(1):620. doi: 10.1186/s12884-022-04953-z.
3
COVID-19-associated opportunistic infections: a snapshot on the current reports.COVID-19 相关机会性感染：当前报告简述。
Clin Exp Med. 2022 Aug;22(3):327-346. doi: 10.1007/s10238-021-00751-7. Epub 2021 Aug 23.
本文引用的文献
1
Severe acute toxoplasmosis infection following ustekinumab treatment in a patient with psoriasis vulgaris.一名寻常型银屑病患者接受乌司奴单抗治疗后发生严重急性弓形虫感染。
BMJ Case Rep. 2019 Aug 15;12(8):e230415. doi: 10.1136/bcr-2019-230415.
2
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.依奇珠单抗治疗中重度斑块型银屑病患者的长期安全性：来自 11 项临床试验的综合分析。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):333-339. doi: 10.1111/jdv.15242. Epub 2018 Nov 22.
3
Cerebral toxoplasmosis in a patient on methotrexate and infliximab for rheumatoid arthritis.一名类风湿关节炎患者在接受甲氨蝶呤和英夫利昔单抗治疗时发生脑弓形虫病。
Intern Med. 2015;54(11):1433-6. doi: 10.2169/internalmedicine.54.3977. Epub 2015 Jun 1.
4
Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.类风湿关节炎的生物疗法与机会性感染的风险：一项荟萃分析。
Clin Infect Dis. 2014 Jun;58(12):1649-57. doi: 10.1093/cid/ciu185. Epub 2014 Mar 18.
5
Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis.类风湿关节炎患者使用阿达木单抗治疗后发生的脑弓形虫病
Rheumatology (Oxford). 2014 Feb;53(2):284. doi: 10.1093/rheumatology/ket364. Epub 2013 Nov 4.
6
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.肿瘤坏死因子抑制剂治疗新使用者中的非病毒性机会性感染：生物治疗安全性评估（SABER）研究结果
Ann Rheum Dis. 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407. Epub 2013 Jul 13.
7
Toxoplasmosis.弓形虫病
Handb Clin Neurol. 2013;114:125-45. doi: 10.1016/B978-0-444-53490-3.00008-X.
8
Disseminated toxoplasmosis in non-allografted patients with hematologic malignancies: report of two cases and literature review.非移植患者血液恶性肿瘤播散性弓形虫病：两例报告及文献复习。
Eur J Clin Microbiol Infect Dis. 2013 Oct;32(10):1259-68. doi: 10.1007/s10096-013-1879-8. Epub 2013 Apr 18.
9
Risk factors for Toxoplasma gondii infection in the United States.美国弓形虫感染的风险因素。
Clin Infect Dis. 2009 Sep 15;49(6):878-84. doi: 10.1086/605433.
10
Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis.类风湿关节炎中的弓形虫性脉络膜视网膜炎与抗肿瘤坏死因子治疗
Semin Arthritis Rheum. 2007 Feb;36(4):262-3. doi: 10.1016/j.semarthrit.2006.08.004. Epub 2006 Oct 25.
Zotero 插件